SOURCE: Dako Denmark A/S

November 25, 2008 07:16 ET

Dako enters new collaboration with Genentech on a companion diagnostic for a targeted cancer therapy

GLOSTRUP, DENMARK--(Marketwire - November 25, 2008) - Dako, worldwide provider of cancer diagnostic solutions, has signed an agreement with Genentech, Inc., a US-based biotechnology company, for a drug-companion diagnostic co-development program for a targeted cancer therapy.

The collaboration involves the use of Dako's extensive experience in developing cancer diagnostic tests to identify cancer patients who may receive greater benefits from a certain therapy.

Under the terms of the agreement Dako and Genentech will collaborate on developing a new cancer diagnostic test as a potential companion product for a specific Genentech investigational therapeutic.

The collaboration is in line with Dako's ongoing strategy to combine its strengths with biotechnology and pharmaceutical companies to develop the offering of Dako's Pharmacodiagnostic™ assays.

"We are very pleased to announce our collaboration with Genentech to potentially further expand the market for targeted therapies. We see a great potential in a strong collaborative approach between biotechnology and pharmaceutical companies and diagnostic companies in targeting the right drugs for the right patients, both to improve patient care and more efficiently managing health care costs," says Patrik Dahlén, CEO and President of Dako Denmark A/S.

"We believe the new collaboration with Genentech recognizes Dako's position in the clinical diagnostics market and as a strong partner for developing diagnostic tests for use in conjunction with drug therapies."

Media contact:
Dako A/S
Lillian Lykke Andersen, Corporate Communications
Mobil: +45 4092 2209

Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics. Hospital and research laboratories worldwide use Dako's knowledge, reagents, instruments and software to make precise diagnoses and determine the most effective treatment for patients suffering from cancer. Employing more than 1000 people and operating in more than 70 countries, Dako covers essentially all of the global anatomic pathology markets. Dako is owned by a private equity fund, EQT.

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Copyright © Hugin AS 2008. All rights reserved.

Contact Information